Up to 52% of patients on retatrutide went from severe apnea to mild or none over 80 weeks, against 13% on placebo, researchers report. The drug isn't approved yet.
Recap by typeshit. Full story at PravdaReport.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
The update also rounds up the Awiqli pediatric approval, CagriSema subgroup data and the lost ad injunction against Lilly ahead of November 4 results.
STAT
Top-dose patients cut A1c by 2.2 points and lost 20.9% of body weight, versus 1.8 points and 9.4% on Ozempic, per Lilly's on-treatment analysis.
Loading…